Covered recipient · General Payments record
KIMBERLEY ANNE KLECKNER
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$1,599.22
- Reported across 62 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $763.86 | 35 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $236.62 | 14 |
| Lilly USA, LLC | $233.21 | 6 |
| PFIZER INC. | $124.42 | 7 |
| ABBVIE INC. | $111.83 | 5 |
| Acerta Pharma LLC | $29.60 | 2 |
| GlaxoSmithKline, LLC. | $28.18 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (35)
Sorted by paying entity, then date · as published by CMS
Program year 2024 20182023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $20.89 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104083664 | CMS |
| ABBVIE INC. | $34.06 | 04/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104083666 | CMS |
| ABBVIE INC. | $21.78 | 07/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104083668 | CMS |
| ABBVIE INC. | $16.01 | 08/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104083670 | CMS |
| ABBVIE INC. | $19.09 | 11/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104083672 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.58 | 04/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104536173 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.02 | 12/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104234073 | CMS |
| GlaxoSmithKline, LLC. | $28.18 | 01/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116358104 | CMS |
| Lilly USA, LLC | $27.60 | 01/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135112502 | CMS |
| Lilly USA, LLC | $22.91 | 02/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135132443 | CMS |
| Lilly USA, LLC | $107.61 | 05/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135135708 | CMS |
| Lilly USA, LLC | $24.19 | 06/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135107505 | CMS |
| Lilly USA, LLC | $27.97 | 08/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135132445 | CMS |
| Lilly USA, LLC | $22.93 | 09/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135122943 | CMS |
| Novo Nordisk Inc | $19.69 | 01/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096994123 | CMS |
| Novo Nordisk Inc | $20.34 | 03/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097335861 | CMS |
| Novo Nordisk Inc | $8.34 | 03/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097534943 | CMS |
| Novo Nordisk Inc | $11.43 | 05/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097508671 | CMS |
| Novo Nordisk Inc | $15.44 | 05/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097234928 | CMS |
| Novo Nordisk Inc | $8.44 | 06/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096773624 | CMS |
| Novo Nordisk Inc | $18.63 | 07/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096893181 | CMS |
| Novo Nordisk Inc | $21.85 | 07/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096907005 | CMS |
| Novo Nordisk Inc | $12.14 | 08/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097641051 | CMS |
| Novo Nordisk Inc | $18.67 | 08/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096911850 | CMS |
| Novo Nordisk Inc | $22.74 | 10/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096827163 | CMS |
| Novo Nordisk Inc | $23.31 | 10/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096809776 | CMS |
| Novo Nordisk Inc | $17.94 | 11/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096916036 | CMS |
| Novo Nordisk Inc | $17.66 | 12/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096992906 | CMS |
| PFIZER INC. | $15.21 | 01/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131093520 | CMS |
| PFIZER INC. | $16.83 | 04/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131362620 | CMS |
| PFIZER INC. | $14.42 | 04/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131341322 | CMS |
| PFIZER INC. | $21.77 | 05/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131519812 | CMS |
| PFIZER INC. | $14.53 | 06/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131427956 | CMS |
| PFIZER INC. | $15.09 | 09/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131836476 | CMS |
| PFIZER INC. | $26.57 | 10/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131166897 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.